Standout Papers

Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome 2012 2026 2016 2021 1.4k
  1. Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (2012)
    Gregory G. Schwartz, Anders Olsson et al. New England Journal of Medicine
  2. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol (2020)
    Kausik K. Ray, R. Scott Wright et al. New England Journal of Medicine
  3. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol (2017)
    Kausik K. Ray, Ulf Landmesser et al. New England Journal of Medicine
  4. A Highly Durable RNAi Therapeutic Inhibitor of PCSK9 (2016)
    Kevin Fitzgerald, Anna Borodovsky et al. New England Journal of Medicine
  5. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia (2020)
    Frederick J. Raal, David Kallend et al. New England Journal of Medicine
  6. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial (2011)
    Zahi A. Fayad, Venkatesh Mani et al. The Lancet
  7. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis (2021)
    R. Scott Wright, Kausik K. Ray et al. Journal of the American College of Cardiology
  8. Inclisiran and cardiovascular events: a patient-level analysis of phase III trials (2022)
    Kausik K. Ray, Frederick J. Raal et al. European Heart Journal

Immediate Impact

6 by Nobel laureates 8 from Science/Nature 86 standout
Sub-graph 1 of 18

Citing Papers

Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
Possibilities and limitations of antisense oligonucleotide therapies for the treatment of monogenic disorders
2024 Standout
9 intermediate papers

Works of David Kallend being referenced

Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
2020 Standout
A Highly Durable RNAi Therapeutic Inhibitor of PCSK9
2016 Standout
and 14 more

Author Peers

Author Last Decade Papers Cites
David Kallend 5136 2483 1103 1737 98 7.4k
Sergio Fazio 4418 2197 796 1845 141 7.7k
Michael Clearfield 5774 2958 1612 2132 64 8.4k
G. Kees Hovingh 7161 3865 1438 2559 203 11.2k
Gregory G. Schwartz 6233 2810 1285 3596 196 9.9k
Dirk Blom 6109 2183 1861 1936 157 7.9k
Michael J. Koren 6258 2017 2421 3757 99 10.0k
Georgina Buck 3524 1596 1290 1404 53 9.7k
Michael Szarek 3713 3156 661 2204 120 7.0k
Brian A. Ference 3426 1947 856 1514 66 6.0k
David W. Bilheimer 4618 2229 404 1325 61 7.4k

All Works

Loading papers...

Rankless by CCL
2026